ArticleEuropean journal of medical research2025
The role of CSTF2 in gastric cancer: implications for therapy.
Article in European journal of medical research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
backgroundGastric cancer is a fatal malignancy that is frequently diagnosed at an advanced stage worldwide, and current treatments are limited. The RNA-binding protein CSTF2 is associated with the prognosis of many cancers, but the role it plays in gastric cancer remains unknown.
methodsWe collected tissues of gastric cancer and adjacent ones paired adjacent non-tumor tissues at the First Affiliated Hospital of Anhui Medical University. CSTF2 expression was initially detected using immunohistochemistry and Western blotting, and its association with clinicopathological features was assessed. Knockdown of CSTF2 in gastric carcinoma cell models was conducted to examine the effect on cell proliferation, migration, and invasion. The mRNA stability of downstream targets was assessed by actinomycin D assay. Further RNA sequencing analysis revealed the downstream influential genes of CSTF2, especially TGM2. Afterwards, the function of TGM2 and its interactions with CSTF2 were further verified.
resultsThe production of CSTF2 was markedly higher in gastric cancer tissues compared to adjacent noncancerous tissues and showed a strong correlation with poor patient prognosis. CSTF2 inhibition significantly suppressed gastric cancer cell growth, proliferation, migration, and invasion. Mechanistically, CSTF2 knockdown accelerated the decay of TGM2 mRNA, indicating that CSTF2 post-transcriptionally stabilizes TGM2 transcripts. Further gene expression analysis revealed that TGM2 might serve as a key downstream effector of CSTF2. Ectopic expression of TGM2 partially rescued the inhibitory effect of CSTF2 deficiency on cell proliferation and colony formation.
conclusionsCSTF2 promotes gastric cancer progression by post-transcriptionally stabilizing TGM2 mRNA, and its overexpression is closely related to poor prognosis. The elucidated CSTF2-TGM2 regulatory axis may offer a promising and innovative therapeutic target for gastric carcinoma treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.